Supplement · graded by use, two uses
Collagen Peptides
Activity-related joint pain in athletes and active adults.
Collagen powder is made from the skin, bones or scales of cows, pigs or fish. In three studies of athletes and active adults, people taking collagen reported less joint pain during exercise than people taking a dummy powder. That result rests on how people said they felt. For skin, the evidence is weak: the benefit showed up mainly in studies paid for by companies, and not in independent ones. Collagen does not replace protein from food.
The B belongs to one of the two uses graded on this record. The other one carries its own letter.
As studied, and the trials
Three randomized placebo-controlled trials agree. Clark et al. (Curr Med Res Opin, 2008; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 18416885): 147 athletes with activity-related joint pain, 10 g/day for 24 weeks, 97 evaluable; five self-rated pain parameters and one physician-rated parameter improved against placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received.; funding not stated. Zdzieblik et al. (Appl Physiol Nutr Metab, 2017; PMID 28177710): 139 athletes with functional knee pain, 5 g/day for 12 weeks; activity-related pain, the primary outcome, improved against placebo (p = 0.046); one author at an industry collagen research institute. Kviatkovsky et al. (J Int Soc Sports Nutr, 2023; PMID 37551682): middle-aged active adults, 10 or 20 g/day for 9 months; KOOS pain and daily-living scores improved at 10 g/day over 6 months, the pain effect only in those exercising more than 180 minutes a week; NIH training grant, no conflicts reported. Replicated The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. randomized evidence on self-reported pain: B, the ceiling for self-report. The three trials span unstated, industry-affiliated and independent funding, so no single funder stands behind the letter.
As studied, and the trials
Myung and Park (Am J Med, 2025; PMID 40324552): meta-analysis A study that pools the numbers from several trials into one combined estimate. of 23 randomized trials, 1,474 participants; positive overall for hydration, elasticity and wrinkles, but null in trials without company funding and null in high-quality trials, so the positive results are concentrated in company-funded trials. Pu et al. (Nutrients, 2023; PMID 37432180): 26 trials, 1,721 participants, hydration and elasticity improved with several biases noted. A pooled result that disappears in the independent and the high-quality trials is mixed evidence: C.
Read the grade that matches your goal. How EBL grades by use →
A letter describes the human evidence, not the product, the manufacturer, or the ingredient's worth.
See the full evidence record →Activity-related joint pain in athletes and active adults, three randomized placebo-controlled trials in agreement.
Why this gradeThe reasoning, and what the grade does not cover.
Grade B, the record's best use: activity-related joint pain in athletes and active adults, where three randomized placebo-controlled trials agree. Clark et al. (Curr Med Res Opin, 2008; PMID 18416885; 147 athletes, 24 weeks), Zdzieblik et al. (Appl Physiol Nutr Metab, 2017; PMID 28177710; 139 athletes, 12 weeks) and Kviatkovsky et al. (J Int Soc Sports Nutr, 2023; PMID 37551682; middle-aged active adults, 9 months) each found self-reported activity-related pain lower than placebo. Replicated randomized evidence on a self-reported endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. is B, and self-report is what keeps it from A. The three trials span unstated, industry-affiliated and independent funding, so no single funder stands behind the letter.
SKIN CARRIES ITS OWN CMyung and Park (Am J Med, 2025; PMID 40324552) found the pooled benefit on hydration, elasticity and wrinkles disappears in trials without company funding and in high-quality trials, and Pu et al. (Nutrients, 2023; PMID 37432180) note several biases; a pooled result that depends on funded trials is mixed. The bundled headline was moved B to C in October 2026 because the uses were mixed together; split in October 2026 by the written rule, each use carries its own letter and the headline follows the best.
WHAT THIS GRADE DOES NOT COVERbone density, where one 12-month trial in postmenopausal women (König et al., 2018; PMID 29337906) is noted but not graded; gelatin with vitamin C as a separate preparation (Shaw et al., 2017; PMID 27852613); knee osteoarthritis, a clinical population the joint trials did not enroll; and people who do not exercise, in whom the largest trial found no pain effect.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Trials report an average. This box says whether any trial on this record looked at who the result applies to, and what it found.
For Activity-related joint pain in athletes and active adults, Grade B · Subgroup tested, effect differedKviatkovsky et al. (J Int Soc Sports Nutr, 2023; PMID 37551682) found the pain effect only in participants exercising more than 180 minutes a week. A subgroup result shows who the effect appeared in within these trials. It does not change the letter.
As studied: dose, form, population and duration for every use
A grade describes the intervention that was tested. Where the product on the shelf differs from it, this says so.
How this letter has changed · latest: October 2026 · Upgraded
The headline moved B to C in October because joint pain and skin were bundled and the evidence across them was mixed. Graded by use, as the decision sheet proposed: activity-related joint pain in athletes and active adults rests on three randomized placebo-controlled trials that agree (Clark et al., 2008; PMID 18416885; Zdzieblik et al., 2017; PMID 28177710; Kviatkovsky et al., 2023; PMID 37551682), replicated randomized evidence on self-reported pain, B at the self-report ceiling; skin rests on pooled analyses whose benefit disappears in independent and high-quality trials (Myung and Park, 2025; PMID 40324552; Pu et al., 2023; PMID 37432180), mixed, C. The headline follows the best use to B. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).PMID 18416885 PMID 28177710 PMID 37432180 PMID 37551682 PMID 40324552
The dose line said trials dosed collagen alongside vitamin C; only Shaw 2017 (PMID 27852613) did, and that was an 8-man, 3-day study of vitamin C-enriched gelatin measuring a synthesis marker, now labeled mechanistic context. Clark 2008 (PMID 18416885) used 10 g and Zdzieblik 2017 (PMID 28177710) 5 g without vitamin C; corrected. Choi 2019 (PMID 30681787) is a qualitative review, not a meta-analysis, and is relabeled; the meta-analysis flag now rests on Myung and Park 2025 (PMID 40324552), null in independent and high-quality skin trials, and Pu 2023 (PMID 37432180), positive with biases noted and no difference by collagen source, which also removes the unsupported marine-versus-bovine preference. Kviatkovsky 2023 (PMID 37551682), a 9-month trial with an NIH training grant, is added on joint pain. König 2018 (PMID 29337906), a 12-month bone-density trial, is noted and not graded. Letter unchanged; the joint-pain split is on the decision sheet.PMID 27852613 PMID 18416885 PMID 28177710 PMID 30681787 PMID 40324552 PMID 37432180 PMID 37551682 PMID 29337906
Collagen held one B across joint and skin uses. Joint pain rests on small self-reported trials in athletes (Clark et al., Curr Med Res Opin 2008; PMID 18416885; Zdzieblik et al., Appl Physiol Nutr Metab 2017; PMID 28177710). For skin, Myung et al. (Am J Med 2025; PMID 40324552) found no effect in trials without industry funding and in high-quality trials. Mixed across the named uses: C. Editor adjudication, October 2026.PMID 18416885 PMID 28177710 PMID 40324552
Funding stated in the evidence. The knee-pain trial Zdzieblik 2017 (PMID 28177710) has a Collagen Research Institute author, and the skin meta-analysis Myung 2025 (PMID 40324552) found no effect in trials without industry funding, so the positive skin results come from company-funded trials. Letter unchanged.PMID 28177710 PMID 40324552
Every change to a letter on this site is dated and published. The full evidence log →
Commercial disclosure
EBL earns no commission on any supplement it grades. A purchase made through the dispensary link below pays EBL nothing, the practitioner discount goes to you in full. The dispensary is Fullscript, a practitioner dispensary, and many of the professional-grade brands in it are sold mainly through practitioners rather than in health food stores. Grades are assigned by published rubric before any commercial relationship exists and are never influenced by one. Full disclosure.
5 to 20 g/day hydrolyzed collagen peptides in the joint-pain trials: 10 g/day for 24 weeks (Clark 2008, PMID 18416885), 5 g/day for 12 weeks (Zdzieblik 2017, PMID 28177710), 10 or 20 g/day for 9 months (Kviatkovsky 2023, PMID 37551682). None of these added vitamin C. Vitamin C was co-administered only in the 3-day gelatin study (Shaw 2017, PMID 27852613), a different preparation.
Hydrolyzed collagen (collagen peptides) is the form used in the joint-pain trials; gelatin with vitamin C is a different preparation studied only for a collagen-synthesis marker. No retrieved trial or meta-analysis supports choosing marine over bovine collagen or the reverse: Pu 2023 (PMID 37432180) found no difference by collagen source for skin elasticity.
In the cited collagen-synthesis study, vitamin C-enriched gelatin was taken one hour before a short bout of exercise (PMID 27852613); that is a different preparation. The summaries of the joint-pain trials do not state a time (PMID 18416885, PMID 28177710, PMID 37551682).
Checked against the published summaries; the full papers could not be read. What the cited trials did, not a schedule. Every supplement, by trial timing →
Allergy to the source species, usually bovine, porcine or marine. Collagen is not a complete protein and does not substitute for dietary protein, which is a nutrition point rather than a safety one.
No prominent drug interaction has been identified. Calcium content in marine and bovine collagen preparations can be meaningful at high intakes, which matters alongside calcium supplementation or in hypercalcemia.
The calcium question is a nutrient load, and one trial has co-administered them. The record notes that marine and bovine collagen preparations can carry meaningful calcium, which matters alongside calcium supplementation. This is a dose-stacking question rather than a pharmacological interaction, and a randomized trial has put the two together deliberately. In 51 postmenopausal women with osteopenia, one arm took a sachet of 5 g collagen peptides with 3.6 g calcium lactate, equal to 500 mg of elemental calcium, plus 400 IU of vitamin D, against a comparator tablet delivering the same 500 mg of elemental calcium. The trial matched the calcium load precisely, which is exactly the arithmetic a reader taking both needs to do and the reason the caution belongs on the page. No trial has reported hypercalcemia from collagen preparations, and none has measured collagen against a calcium-handling drug. Argyrou et al. (J Musculoskelet Neuronal Interact, 2020;20(1):12-17; PMID 32131366): randomized study of calcium and vitamin D with and without collagen peptides on bone turnover in postmenopausal women with osteopenia.
Joint pain scores, skin elasticity (clinical photography), bone density (DEXA) if primary indication
Primary evidenceEight papers, each linked to its PubMed record.
Joint pain: Clark et al. (Curr Med Res Opin, 2008; PMID 18416885): 147 varsity and club athletes with activity-related joint pain, 10 g/day collagen hydrolysate for 24 weeks, data evaluable in 97; five self-rated pain parameters and one physician-rated parameter improved against placebo. Funding is not stated in its indexed record. Zdzieblik et al. (Appl Physiol Nutr Metab, 2017; PMID 28177710): 139 athletes with functional knee pain, 5 g/day specific collagen peptides for 12 weeks; activity-related pain on a visual analogue scale, the primary outcome, improved against placebo (p = 0.046), resting pain did not; one of its authors is at the Collagen Research Institute, Kiel, an industry research body. Kviatkovsky et al. (J Int Soc Sports Nutr, 2023; PMID 37551682): 9-month double-blind Neither the participants nor the people assessing them know who received the real treatment until the trial ends. trial in middle-aged active adults, placebo versus 10 or 20 g/day; KOOS pain and activities-of-daily-living scores improved at 10 g/day over 6 months, the pain effect only in those exercising more than 180 minutes a week; the paper lists an NIH training grant and reports no conflicts. Skin: Myung and Park (Am J Med, 2025; PMID 40324552): meta-analysis of 23 randomized trials, 1,474 participants, positive overall for hydration, elasticity and wrinkles, but null in trials without company funding and null in high-quality trials, so the positive skin results are concentrated in company-funded trials. Pu et al. (Nutrients, 2023; PMID 37432180): meta-analysis of 26 randomized trials, 1,721 participants, hydration and elasticity improved, with several biases noted and no difference in elasticity by collagen source. Choi et al. (J Drugs Dermatol, 2019; PMID 30681787): qualitative systematic review A review that searches for every study on a question using a method set in advance, then assesses them together. of 11 trials, not a meta-analysis; context. Mechanistic context, not graded: Shaw et al. (Am J Clin Nutr, 2017; PMID 27852613): 8 men, 3 days, crossover A trial design in which each participant receives both the treatment and the comparison, one after the other, and serves as their own control. of vitamin C-enriched gelatin, measuring a blood collagen-synthesis marker and engineered ligaments in the laboratory; funded by the National Institute on Aging; a different preparation and a surrogate marker A lab value or measurement used in place of the outcome that matters, such as LDL cholesterol standing in for heart attacks. Moving a surrogate does not always move the outcome.. Bone, not graded here: König et al. (Nutrients, 2018; PMID 29337906): 131 postmenopausal women, 5 g/day specific collagen peptides for 12 months, spine and femoral neck bone density higher than placebo; one author is at the Collagen Research Institute.
Educational use only · Not medical advice · Starting, stopping or changing any supplement or medication is a decision for your physician
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
This page carries a letter. EBL takes no commission, referral fee or payment of any kind on anything it grades. No letter has been bought and none is for sale.
How this is enforced
That is not a promise, it is a build condition. Two checks run on every deploy: one refuses to publish if a commission is claimed on anything graded, the other refuses if a page names a commercial relationship that is not declared in the register. If either fails, this page does not go live. You can read how the checks work, and what they do not cover, on the evidence integrity page.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
"collagen peptide*"[tiab] AND (joint[tiab] OR skin[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt])Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →